Scandinavian Biopharma reports successful results of the oral, inactivated ETEC vaccine candidate ETVAX® against enterotoxigenic E. coli diarrhoea in a placebo-controlled phase I/II study in infants and children from 6 months to 5 years of age in Bangladesh

The successful results of the Phase I/II study in Dhaka, Bangladesh, are now published in The Lancet Infectious Diseases. All predefined primary endpoints for the study were achieved and exceeded, showing that the vaccine candidate was safe and broadly immunogenic, stimulating immune responses to all key vaccine components. Only a few mild to moderate adverse […]